Parameter | Overall cohort | Group1 (3–4 × 106 CD34+ cells/kg bw) | Group 2 (2–2.5 × 106 CD34+ cells /kg bw) | P value Group 1 vs. 2 | Group 3 (< 2 × 106 CD34+ cells /kg bw) |
---|---|---|---|---|---|
Patient number, n | 148 | 86 | 53 | / | 9 |
Sex, n (%) | Â | Â | Â | 0.030 | Â |
 Male | 87 (59) | 44 (51) | 37 (70) | 6 (67) | |
 Female | 61 (41) | 42 (49) | 16 (30) | 3 (33) | |
Diagnosis of MM, n (%) | |||||
 Median age at first diagnosis, years (range) | 60 (41–72) | 60 (44–72) | 61 (41–71) | 0.854 | 60 (46–72) |
 Stage at first diagnosis |  |  |  | / |  |
  I | 7 (5) | 4 (5) | 3 (6) | 9 (100) | |
  II | 4 (3) | 3 (3) | 1 (2) | 0 (0) | |
  III | 136 (92) | 79 (92) | 48 (91) | 0 (0) | |
  NA | 1 (1) | 0 (0) | 1 (2) | 0 (0) | |
  A | 129 (87) | 78 (91) | 44 (83) | / | 7 (78) |
  B | 18 (12) | 8 (9) | 8 (15) | 2 (22) | |
  NA | 1 (1) | 0 (0) | 1 (2) | 0 (0) | |
 Heavy chain type |  |  |  | 0.767a |  |
  IgG | 95 (64) | 56 (65) | 37 (70) | 2 (22) | |
  IgA | 29 (20) | 17 (20) | 8 (15) | 4 (44) | |
  IgD | 1 (1) | 1 (1) | 0 (0) | 0 (0) | |
  Light chain only | 23 (16) | 12 (14) | 8 (15) | 3 (33) | |
 Light chain type |  |  |  | 0.452 |  |
  kappa | 96 (65) | 53 (62) | 36 (68) | 7 (78) | |
  lambda | 52 (35) | 33 (38) | 17 (32) | 2 (22) | |
Induction therapy, n (%) | |||||
 Median number of cycles (range) | 4 (2–8) | 4 (2–6) | 4 (3–8) |  | 4 (3–5) |
  VCD | 70 (47) | 39 (45) | 28 (53) | 0.297b | 3 (33) |
  VRD | 30 (20) | 22 (26) | 8 (15) | 0 (0) | |
  Elotuzumab-VRd | 33 (22) | 22 (26) | 10 (19) | 1 (11) | |
  Other/modifications | 15 (10) | 3 (3) | 7 (13) | 5 (56) | |
Mobilization therapy, n (%) | Â | Â | Â | / | Â |
 1xCAD | 143 (97) | 85 (99) | 50 (94) | 8 (89) | |
 Other | 5 (3) | 1 (1) | 3 (6) | 1 (11) | |
Remission prior PBSC collection, n (%) | |||||
 nCR | 25 (17) | 19 (22) | 5 (9) | 0.041c | 1 (11) |
 VGPR | 52 (35) | 34 (40) | 17 (32) | 1 (11) | |
 PR | 54 (36) | 25 (29) | 25 (47) | 4 (44) | |
 MR | 8 (5) | 5 (6) | 2 (4) | 1 (11) | |
 SD | 1 (1) | 1 (1) | 0 (0) | 0 (0) | |
 NA | 8 (5) | 2 (2) | 4 (8) |  | 2 (22) |